Navigation Links
Aisling Capital Announces Close of US$650M Life Sciences Fund
Date:1/7/2009

NEW YORK, Jan. 7 /PRNewswire/ -- Aisling Capital announced today that it raised US$650 million in committed capital for its newest life sciences fund, Aisling Capital III, LP. Aisling Capital will invest its third fund primarily in companies developing pharmaceutical, biopharmaceutical and medical products, as well as in businesses that provide drug development, manufacturing and other important services to the healthcare industry. With a total of over US$1.6 billion in committed capital under management, the Aisling Capital team will also continue to manage the Perseus-Soros BioPharmaceutical Fund, LP and Aisling Capital II, LP.

"We appreciate the support of our existing and new limited partners, particularly during these times of market turbulence," commented Dennis Purcell, Senior Managing Partner of Aisling Capital. Mr. Purcell added: "We believe the next several years will be a critical period for the life sciences industry, in which multiple forces will converge to create opportunities for the prepared investor."

The Aisling Capital team is comprised of individuals with a combination of clinical, transactional, operational and capital markets expertise, complemented by extensive networks in the life sciences industry. The team is led by Managing Partners Dennis Purcell, Steve Elms and Andrew Schiff, M.D. and newly promoted Partners Dov Goldstein, M.D., Anthony Sun, M.D. and Brett Zbar, M.D. Additionally, Josh Bilenker, M.D. has been promoted to Principal.

About Aisling Capital

Aisling Capital is a dedicated life sciences private equity firm with over US$1.6 billion under management. Headquartered in New York, Aisling Capital invests in both private and public companies utilizing a wide variety of investment structures. The Aisling Capital team's combination of clinical, operational and financial experience allows the firm to identify, execute and realize investments across the life sciences industry.

Web site: http://www.aislingcapital.com


'/>"/>
SOURCE Aisling Capital
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
2. Rigel to Participate at the RBC Capital Markets Healthcare Conference
3. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
4. Micromet to Present at the RBC Capital Markets Healthcare Conference
5. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
6. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
7. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
8. Abaxis, Inc. to Present at the RBC Capital Markets 2008 Healthcare Conference
9. Medarex to Present at the RBC Capital Markets Healthcare Conference
10. Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
11. Jazz Pharmaceuticals Cancels Presentation Planned for November 19, 2008 at Lazard Capital Markets 5th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... ... catheters associated with peritoneal dialysis, announced today that it has published the result ... system in Peritoneal Dialysis International (PDI), the official Journal of the International ...
(Date:2/20/2017)... Fla. , Feb. 20, 2017  Atrius Health ... today entered into an agreement to develop a ... experience. By providing a holistic view of the ... determinants, Watson Cognitive Insights could be designed to ... Atrius Health is an innovative nonprofit healthcare organization ...
(Date:2/18/2017)... ... 17, 2017 , ... The BMT Tandem Meetings of the ... Blood & Marrow Transplant Research (CIBMTR) will take place Feb. 22-26, 2017 at ... scientific sessions offer investigators, clinicians, laboratory technicians, clinical research professionals, nurses, pharmacists, administrators, ...
(Date:2/17/2017)... , February 17, 2017 ... Market by Product (Consumables, Service), Type (Safety, Efficacy, ... Development, Drug Discovery and Development, Disease-Risk) - Global ... is projected to reach USD 53.34 Billion by ... at a CAGR of 13.8% during the forecast ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017 About Voice Recognition Biometrics Voice recognition ... against a stored voiceprint template. Acoustic features of ... tone are compared to distinguish between individual voices. ... most PCs already have a microphone and can ... biometrics are most likely to be deployed in ...
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/3/2017)... , Feb. 3, 2017 A new ... Identity Strategy Partners, LLP (IdSP) . Designed to fill ... the complex identity market, founding partners Mark Crego ... 35 combined years just in identity expertise that span ... and non-profit leadership. The Crego-Kephart combined expertise has a ...
Breaking Biology News(10 mins):